Back to All Combinations

BRAF V600E + MSI-H

Intermediate Prognosis
2.00% Prevalence A General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
BRAF V600E MSI-H
Recommended Treatments
Pembrolizumab
Nivolumab + Ipilimumab
Treatments to Avoid

No specific contraindications noted

Key Statistics
2.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
MSI-H status confers better prognosis even with BRAF mutation. Immunotherapy highly effective.
Information

Category: General

Evidence Level: A

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.